Topic: checkpoint inhibitors

opdivo

6. Opdivo

2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.